DYN - Dyne Therapeutics, Inc.

QQQ $ 613.36 $ -9.99 (-1.61 %)

DIA $ 470.23 $ -2.78 (-0.59 %)

SPY $ 671.96 $ -6.30 (-0.93 %)

TLT $ 89.61 $ 0.21 (0.23 %)

GLD $ 367.27 $ -1.11 (-0.3 %)

Previous Close

$ 18.205

Open

$ 21.06

Bid

$ 17.25 x 600

Ask

$ 20.53 x 1

Day's Range

$ 17.24 - $ 21.18

52 Week Range

$ 6.36 - $ 35.68

Volume

5,272,749

Average Volume

Market Cap

2.6B

Beta (5Y Monthly)

$ 1.28

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Dyne ...
11/06/2025 16:37:03

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target...

RBC Capital Maintains Outperform on Dyne T...
11/06/2025 15:51:26

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $2...

Dyne Therapeutics Q3 EPS $(0.76) Beats $(0...
11/05/2025 22:08:54

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0....

12 Health Care Stocks Moving In Monday's I...
10/27/2025 17:05:57

janus-henderson-avidity-biosciences-bridgebio-pharma-and-other-big-stocks-moving-higher-on-monday

Janus Henderson, Avidity Biosciences, Brid...
10/27/2025 14:21:30

12 Health Care Stocks Moving In Monday's P...
10/27/2025 12:06:22

why-avidity-biosciences-shares-are-trading-higher-by-around-42-here-are-20-stocks-moving-premarket

Why Avidity Biosciences Shares Are Trading...
10/27/2025 08:53:30

Oppenheimer Downgrades Dyne Therapeutics t...
10/10/2025 17:47:16

Oppenheimer analyst Andreas Argyrides downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and maintains the...

Dyne Therapeutics Reveals Additional One-Y...
10/06/2025 22:03:51

WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on del...

Raymond James Upgrades Dyne Therapeutics t...
08/25/2025 14:47:29

Raymond James analyst Martin Auster upgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Strong Buy and raises the pri...

Dyne Therapeutics Shares Resume Trade
08/06/2025 15:25:55

Dyne Therapeutics Shares Halted On Circuit...
08/06/2025 15:22:25

Oppenheimer Maintains Outperform on Dyne T...
08/06/2025 12:12:52

Oppenheimer analyst Andreas Argyrides maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target...

Dyne Therapeutics Receives FDA Breakthroug...
08/04/2025 11:34:42

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. acce...

Stifel Maintains Buy on Dyne Therapeutics,...
07/31/2025 15:50:37

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $66 to $36.

these-analysts-lower-their-forecasts-on-dyne-therapeutics-following-q2-loss

These Analysts Lower Their Forecasts On Dy...
07/29/2025 16:51:38

RBC Capital Maintains Outperform on Dyne T...
07/29/2025 14:39:08

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $2...

Raymond James Reiterates Outperform on Dyn...
07/29/2025 13:55:54

Raymond James analyst Martin Auster reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target ...

Chardan Capital Maintains Buy on Dyne Ther...
07/29/2025 10:35:42

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 ...

Dyne Therapeutics Q2 EPS $(0.97), Inline
07/28/2025 20:29:44

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.97) per share which met the analyst consensus estimate. This is...